Unknown

Dataset Information

0

Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer.


ABSTRACT: Neurocognitive dysfunction is reported in women with breast cancer even prior to receipt of adjuvant therapy; however, there is little understanding of underlying mechanisms. We tested the hypothesis that pretreatment neurocognitive dysfunction in newly diagnosed patients is related to immunological activation, as indexed by pro-inflammatory cytokines. One hundred seventy-four postmenopausal patients with newly diagnosed breast cancer underwent a comprehensive neuropsychological evaluation (assessment of cognitive function, mood, and fatigue) and measurement of key cytokine levels prior to surgery. Age-matched control participants without cancer were evaluated concurrently. Multivariable regression analyses examined the contribution of circulating Interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1ra), and soluble TNF receptor type two (sTNF-RII) in predicting neurocognitive performance in patients after controlling for key factors thought to impact functioning. All tests of statistical significance were two-sided. Memory performance was statistically significantly reduced, in patients compared with controls (P = .02). Of the three cytokines measured, only IL-1ra was statistically significantly elevated in cancer patients when compared with control participants (mean ± SD, 375 ± 239 pg/mL vs 291 ± 169 pg/mL, P = .007). After controlling for age, education, race, mood, fatigue, body mass index, and comorbidity, cytokines independently explained 6.0% of the total variance in memory performance (P = .01) in cancer patients but not control participants, with higher sTNF-RII associated with worse functioning. Exploratory analyses found that comorbidity statistically significantly explained variance in processing speed and executive functioning (P = .03 and P = .03, respectively). An association of TNF with memory, previously reported in patients after exposure to chemotherapy, was found prior to initiation of any treatment, including surgery. This association requires further investigation as sTNF-RII was not higher in cancer patients relative to control participants.

SUBMITTER: Patel SK 

PROVIDER: S-EPMC4609551 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer.

Patel Sunita K SK   Wong Andrew L AL   Wong F Lennie FL   Breen Elizabeth Crabb EC   Hurria Arti A   Smith Mackenzie M   Kinjo Christine C   Paz I Benjamin IB   Kruper Laura L   Somlo George G   Mortimer Joanne E JE   Palomares Melanie R MR   Irwin Michael R MR   Bhatia Smita S  

Journal of the National Cancer Institute 20150622 8


<h4>Background</h4>Neurocognitive dysfunction is reported in women with breast cancer even prior to receipt of adjuvant therapy; however, there is little understanding of underlying mechanisms. We tested the hypothesis that pretreatment neurocognitive dysfunction in newly diagnosed patients is related to immunological activation, as indexed by pro-inflammatory cytokines.<h4>Methods</h4>One hundred seventy-four postmenopausal patients with newly diagnosed breast cancer underwent a comprehensive n  ...[more]

Similar Datasets

| S-EPMC8020152 | biostudies-literature
| S-EPMC5626589 | biostudies-literature
| S-EPMC7649092 | biostudies-literature
| S-EPMC5148071 | biostudies-literature
| S-EPMC10509734 | biostudies-literature
| S-EPMC3718062 | biostudies-literature
| S-EPMC8854387 | biostudies-literature
| S-EPMC6402990 | biostudies-literature
| S-EPMC10516482 | biostudies-literature
| S-EPMC6378550 | biostudies-literature